Blackstone Inc’s Nurix Therapeutics NRIX Stock Holding History

Blackstone Inc’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,119	Closed	-$399K	–	191
2024 Q1	$399K	Hold	27,119	–	–	﹤0.01%	157
2023 Q4	$280K	Hold	27,119	–	–	﹤0.01%	150
2023 Q3	$213K	Hold	27,119	–	–	﹤0.01%	146
2023 Q2	$271K	Hold	27,119	–	–	﹤0.01%	143
2023 Q1	$241K	Hold	27,119	–	–	﹤0.01%	149
2022 Q4	$298K	Hold	27,119	–	–	﹤0.01%	147
2022 Q3	$353K	Buy	27,119 +10,257	+61%	+$162K	﹤0.01%	172
2022 Q2	$214K	Hold	16,862	–	–	﹤0.01%	217
2022 Q1	$236K	Buy	16,862 +2,674	+19%	+$47.5K	﹤0.01%	212
2021 Q4	$411K	Hold	14,188	–	–	﹤0.01%	354
2021 Q3	$425K	Buy	+14,188	New	+$438K	﹤0.01%	416

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Blackstone Inc's NRIX Position: Q2 2024 in Review

Blackstone Inc sold out of Nurix Therapeutics (NRIX) in Q2 2024, closing a stake of 27,119 shares — an estimated $399K sold.

Blackstone Inc first reported a position in NRIX in Q3 2021 and held it in 11 quarters. The position peaked at $425K in Q3 2021. 173 funds tracked by Wall St. Rank hold NRIX as of Q2 2024.

Blackstone Inc reported no remaining Nurix Therapeutics position as of Q2 2024 after selling out during the quarter.
Blackstone Inc sold 27,119 Nurix Therapeutics shares in Q2 2024, an estimated $399K.
Blackstone Inc first reported a position in Nurix Therapeutics in Q3 2021 and held it in 11 quarters.
Blackstone Inc's Nurix Therapeutics position peaked at $425K in Q3 2021.
173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2024.

Based on Blackstone Inc's 13F filing for Q2 2024, filed 14 Aug 2024.